Ajax Therapeutics de-stealths with $95 million Series C financing

13 May 2024
money_fundraising_round_large

USA-based biotech Ajax Therapeutics today announced the completion of an oversubscribed $95 million Series C financing, led by Goldman Sachs with participation from new investors, including Eli Lilly (NYSE: LLY), and existing investors.

The company also announced it has received US Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for lead candidate AJ1-11095, a first-in-class Type II JAK2 inhibitor myelofibrosis.

With the FDA clearance of its IND, Ajax noted that AJ1-11095 will be the first Type II JAK2 Inhibitor to enter the clinic – with a Phase I study in myelofibrosis planned to begin in 2H 2024.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology